Literature DB >> 12967471

Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E.

Masabumi Shibuya1.   

Abstract

Vascular endothelial growth factor receptor-2 (VEGFR-2/KDR/Flk-1) is a high-affinity receptor for vascular endothelial growth factor-A (VEGF-A), and mediates most of the endothelial growth and survival signals from VEGF-A. VEGFR-2 has a typical tyrosine kinase receptor structure with seven immunoglobulin (Ig)-like domains in the extracellular region, as well as a long kinase insert in the tyrosine kinase domain. It utilizes a unique signaling system for DNA synthesis in vascular endothelial cells, i.e. a phospholipase C gamma-protein kinase C-Raf-MAP kinase pathway. Although VEGF-A binds two receptors, VEGFR-1 and -2, a newly isolated ligand VEGF-E (Orf-virus-derived VEGF) binds and activates only VEGFR-2. Transgenic mice expressing VEGF-E(NZ-7) showed a dramatic increase in angiogenesis with very few side effects (such as edema and hemorrhagic spots), suggesting strong angiogenic signaling and a potential clinical utility of VEGF-E. VEGF family members bear three loops produced via three intramolecular disulfide bonds, and cooperation between loop-1 and loop-3 is necessary for the specific binding and activation of VEGFR-2 for angiogenesis. As it directly upregulates tumor angiogenesis, VEGFR-2 is an appropriate target for suppression of solid tumor growth using exogenous antibodies, small inhibitory molecules and in vivo stimulation of the immune system.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12967471     DOI: 10.1111/j.1349-7006.2003.tb01514.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  31 in total

Review 1.  Interaction of endothelial cells with macrophages-linking molecular and metabolic signaling.

Authors:  Joanna Kalucka; Laura Bierhansl; Ben Wielockx; Peter Carmeliet; Guy Eelen
Journal:  Pflugers Arch       Date:  2017-02-24       Impact factor: 3.657

2.  Fusion with human lung cancer cells elongates the life span of human umbilical endothelial cells and enhances the anti-tumor immunity.

Authors:  Xiyan Mu; Chunju Fang; Jing Zhou; Yufeng Xi; Li Zhang; Yuquan Wei; Tao Yi; Yang Wu; Xia Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2015-07-03       Impact factor: 4.553

3.  A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters.

Authors:  David M Roberts; Amanda L Anderson; Michihiro Hidaka; Raymond L Swetenburg; Cam Patterson; William L Stanford; Victoria L Bautch
Journal:  Mol Cell Biol       Date:  2004-12       Impact factor: 4.272

4.  Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.

Authors:  Ajithkumar Puthillath; Anush Patel; Marwan G Fakih
Journal:  Onco Targets Ther       Date:  2009-02-18       Impact factor: 4.147

5.  The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation.

Authors:  Bernhard Schweighofer; Julia Testori; Caterina Sturtzel; Susanne Sattler; Herbert Mayer; Oswald Wagner; Martin Bilban; Erhard Hofer
Journal:  Thromb Haemost       Date:  2009-09       Impact factor: 5.249

6.  Latent TGFbeta1 overexpression in keratinocytes results in a severe psoriasis-like skin disorder.

Authors:  Allen G Li; Donna Wang; Xin-Hua Feng; Xiao-Jing Wang
Journal:  EMBO J       Date:  2004-04-01       Impact factor: 11.598

7.  Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins.

Authors:  Kelly J Higgins; Shengxi Liu; Maen Abdelrahim; Kathryn Vanderlaag; Xinyi Liu; Weston Porter; Richard Metz; Stephen Safe
Journal:  Mol Endocrinol       Date:  2007-11-15

8.  Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.

Authors:  S Yasuda; M Sho; I Yamato; H Yoshiji; K Wakatsuki; S Nishiwada; H Yagita; Y Nakajima
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

9.  A DNA vaccine against extracellular domains 1-3 of flk-1 and its immune preventive and therapeutic effects against H22 tumor cell in vivo.

Authors:  Fan Lü; Zhao-Yin Qin; Wen-Bin Yang; Yin-Xin Qi; Yi-Min Li
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

10.  Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed.

Authors:  Beth A Tamburini; Susan Trapp; Tzu Lip Phang; Jill T Schappa; Lawrence E Hunter; Jaime F Modiano
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.